Since MelanA/MART-1 is the most frequent target of CD8+ T-cells responses against melanoma in vitro and in vivo [20,73], we constructed a HSV-1 d106S-based oncolytic virus, which expressed the melanoma-associated antigen MelanA/MART-1 in melanoma cells not naturally expressing this tumor antigen [74]. The gene discussed is CD8A; the disease is melanoma.